Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
Authors:
- Erika MartinelliErika Martinelli
- Teresa TroianiTeresa Troiani
- Floriana MorgilloFloriana Morgillo
- Gabriella RodolicoGRGabriella Rodolico
- Donata VitaglianoDVDonata Vitagliano
- Maria Pia MorelliMMMaria Pia Morelli
- Concetta TuccilloCTConcetta Tuccillo
- Loredana VecchioneLVLoredana Vecchione
- Anna CapassoAnna Capasso
- Michele OrdituraMichele Orditura
- Ferdinando De VitaFVFerdinando De Vita
- S. Gail EckhardtSES. Gail Eckhardt
- 13 October 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (20) , 4990-5001
Abstract
Purpose: Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of sorafenib and erlotinib or cetuximab. Experimental Design: Sorafenib, erlotinib, and cetuximab, alone or in combination, were tested in vitro in a panel of non–small cell lung cancer (NSCLC) and colorectal cancer cell lines and in vivo in H1299 tumor xenografts. Results: Epidermal growth factor receptor (EGFR) ligand mRNAs were expressed in all NSCLC and colorectal cancer cell lines with variable levels ranging from 0.4- to 8.1-fold as compared with GEO colorectal cancer cells. Lung cancer cells had the highest levels of vascular endothelial growth factors (VEGF) A, B, and C, and of VEGF receptors as compared with colorectal cancer cells. Combined treatments of sorafenib with erlotinib or cetuximab produced combination index values between 0.02 and 0.5, suggesting a significant synergistic activity to inhibit soft agar colony formation in all cancer cell lines, which was accompanied by a marked blockade in mitogen-activated protein kinase and AKT signals. The in vitro migration of H1299 cells, which expressed high levels of both VEGF ligands and receptors, was inhibited by treatment with sorafenib, and this effect was significantly increased by the combination with anti-EGFR drugs. In nude mice bearing established human H1299 xenografts, treatment with the combination of sorafenib and erlotinib or cetuximab caused a significant tumor growth delay resulting in 70 to 90 days increase in mice median overall survival as compared with single-agent sorafenib treatment. Conclusions: Combination treatment with sorafenib and erlotinib or cetuximab has synergistic antitumor effects in human colorectal and lung cancer cells. Clin Cancer Res; 16(20); 4990–5001. ©2010 AACR.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation StudyJournal of Clinical Oncology, 2010
- Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell linesMolecular Cancer Therapeutics, 2009
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClinical and Experimental Immunology, 2009
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor ResistanceClinical Cancer Research, 2009
- Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer CellsClinical Cancer Research, 2008
- Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinasesMolecular Cancer Therapeutics, 2006
- Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinasesBritish Journal of Cancer, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic ImplicationsThe Oncologist, 2000